A comparison of the therapeutic efficacy of a new bispecific monoclonal antibody (bsMAb)-pretargeting system vs the conventional direct targeting modality was undertaken. A bsMAb was made by coupling the Fab 0 of a humanized anti-CD20 antibody to the Fab 0 of a murine antibody directed against the peptide histamine-succinyl-glycine (HSG). The tumor targeting of the bsMAb was separated from the subsequent delivery of the radionuclide-bearing HSG peptide conjugated with In-anti-CD20 IgG at its highest level on day 7, but by day 1, tumor/blood ratios were about 10-fold higher than the IgG. Tumors progressed rapidly in animals given 800 lCi of 90 Y-HSG peptide alone, whereas 5/10 animals in the group pretargeted by the anti-CD20 bsMAb were tumor-free 18 weeks later. The antitumor response in animals administered the pretargeted 90 Y-HSG peptide was also significantly superior to treatment with the directly radiolabeled 90 Y-anti-CD20 IgG, whether given as a single injection (Po0.007) or as a divided dose (P ¼ 0.016). This bsMAb-pretargeting procedure significantly improves the therapeutic response of targeted radionuclides in non-Hodgkin's lymphoma, warranting further development of this method of radioimmunotherapy.
Introduction
Radiolabeled anti-CD20 monoclonal antibodies (MAbs) have shown a significant and durable response advantage in comparison to naked (unlabeled) anti-CD20 MAbs in patients with indolent and transformed non-Hodgkin's lymphoma (NHL) that have failed prior chemotherapy. [1] [2] [3] [4] These treatments are well tolerated, with a majority of the patients experiencing primarily reversible grade X3 hematological toxicity, but with initial results suggesting no survival benefit compared to unlabeled antibody; hence, further improvements are indicated. Recently, procedures for improving the delivery of targeted radionuclides have been reported, involving so-called pretargeting methods, as reviewed elsewhere. 5 With these pretargeted strategies, a nonradioactive antibody is first administered to bind to the tumor, and then the radioactivity, now attached to a small, rapidly clearing compound, is given later, resulting in higher tumor-to-background ratios and reduced exposure of the bone marrow to circulating radiation. 5 This decreased toxicity improves the therapeutic index and the potential for a more efficacious therapy. 5 These pretargeting methods comprise two basic approaches, either use of streptavidin-biotin systems or employing bispecific antibodies. 5 Using the former method, Press et al 6 reported that improved therapeutic responses were possible using a streptavidin-anti-CD20 IgG conjugate and 90 Y-biotin, when compared to the directly radiolabeled 90 Y-anti-CD20 IgG. Encouraging pilot clinical studies using a rituximab-streptavidin conjugate or an anti-CD20 scFv-streptavidin fusion protein with 90 Y-biotin have also been reported recently. 7, 8 However, clinical studies have indicated that streptavidin is immunogenic, even in NHL patients. 7, 8 We have been investigating pretargeting by means of using bispecific MAbs (bsMAbs) in conjunction with novel peptidehaptens that can be radiolabeled with a variety of radionuclides, including 90 Y. 9, 10 The schema of this pretargeting modality is depicted in Figure 1 . Since the bsMAb constructs can be made by recombinant methods to be over 90% human with only murine binding regions, 10 they should be less immunogenic than agents utilizing streptavidin. Recently, we reported the development of a humanized anti-CD20 antibody that has similar antitumor activity as rituximab both in vitro and in NHL xenograft models. 11 The purpose of this investigation was to assess whether a pretargeting procedure based on a chemically conjugated bsMAb prepared from this humanized anti-CD20 antibody fused with the previously reported anti-peptide-hapten antibody would have a therapeutic advantage over the directly radiolabeled anti-CD20 IgG in an animal model for human NHL.
Materials and methods

Reagent preparation
The humanized anti-CD20 IgG 1 , IMMU-106, 11 and the 1,4,7,10-tetraazacyclododecane-N,N 0 ,N 00 ,N 000 -tetracetic acid (DOTA)-di-HSG hapten-peptide 9 (Supplementary data online Figure 1S ) were provided by Immunomedics Inc. (Morris Plains, NJ, USA), and the murine anti-679 anti-histamine-succinylglycine peptide (HSG) antibody 8 was provided by IBC Pharmaceuticals Inc. (Morris Plains, NJ, USA). The anti-CD20 bsMAb was prepared by chemically conjugating the Fab 0 fragments of IMMU-106 and the anti-HSG MAb, as described previously. Schematic representation of the bispecific antibody-pretargeting procedure. The bispecific antibody is a chemical conjugate composed of the Fab 0 of the IMMU-106 humanized anti-CD20 monoclonal antibody and Fab 011 of a murine antibody (m679) specific for the hapten, HSG.
1 A stable thioether linkage is formed between the two Fab 0 . The bispecific antibody is somewhat smaller than a whole IgG, and therefore it clears from the blood naturally at a faster rate. Once the bispecific antibody sufficiently clears from the blood, the radiolabeled HSGpeptide can be administered. The chemical structure of the HSG-peptide used in these studies is shown in Figure 1S (Supplementary data online). It is composed of single DOTA moiety that is used to stably bind 111 In and 90 Y. The HSG-peptide also has two HSG moieties, which increases the retention of the radiolabeled peptide in the tumor, a process termed affinity enhancement system (AES) by LeDoussal et al. 12 It also could bridge two adjacent bispecific antibodies. The very small size of the radiolabeled peptide allows it to quickly exit the vascular system to bind to the bispecific antibody localized in the tumor, as well as to be very quickly filtered by the kidneys and excreted in the urine.
previously. 9 The immunoreactive fraction for the 125 I-bsMAb exceeded 90% by size-exclusion HPLC, using the 111 In-HSG peptide and a molar excess of the anti-idiotype antibody ( Figure  2S , Supplementary data online).
Animal studies
All animal studies were approved by the responsible institutional animal care and use committee. At approximately 7-9 weeks of age, groups of 25-75 female athymic BALB/c mice (NCI/Charles River Laboratories, Frederick, MD, USA) were implanted s.c. with 1 Â 10 7 Ramos human B-cell lymphoma cells/0.2 ml in the hind flank. When tumors were B1.0 cm diameter, treatments were initiated. For biodistribution studies, mice were injected i.v. with either 50 mg (20 mCi) of 111 In-DOTA-IMMU-106 or 15 mg (0.15 nmol) of the bsMAb containing 8 mCi of 125 I-bsMAb. For pretargeting, the animals were first injected with the bsMAb and then, based on our prior studies using a humanized anti-CEA Fab 0 Â murine anti-HSG Fab 0 bsMAb, the radiolabeled peptide was given when the bsMAb had cleared to o1.0% injected dose per gram (ID/g) in the blood, using a fixed molar ratio of bsMAb/peptide of 10:1 at the amounts indicated. 9, 14 The mice were anesthetized, bled intracardially, and then necropsied at the times indicated. Area under the curve (AUC) was calculated from the biodistribution data using a trapezoidal fit. The radiation-absorbed dose can be derived from the AUC data.
Since Press et al 6 found 800 mCi of 90 Y-biotin to be effective and tolerated in the same Ramos tumor model when using a streptavidin-pretargeting procedure, we decided to also examine 800 mCi of the 90 Y-HSG peptide, as well as a lower dose of 500 mCi of the 90 Y-HSG peptide. For pretargeting, the 90 Y-HSG peptide was given 48 h after the i.v. injection of the bsMAb. Although prior experience with another humanized 90 Y-DOTAIgG in nude mice suggested that a maximum dose of 0.21 mCi could be tolerated, 15 because the body weight of the BALB/c nude mice used in the Ramos model averaged nearly 20% less than the weight of outbred nude mice used previously, the maximum dose tested in these smaller animals was adjusted to 175 mCi for the 90 Y-IMMU-106 IgG. A lower dose of 105 mCi of 90 Y-IMMU-106 IgG was also tested. In addition to examining a single treatment, another set of studies evaluated a fractionated dose schedule. In this study, tumor-bearing nude mice received a second bsMAb injection followed 48 h later with 500 mCi of the 90 Y-HSG peptide 4 weeks after the first treatment. Similarly, animals were given two treatments of 105 mCi of the 90 Y-IMMU-106 IgG, but the interval was shortened to 3 weeks, because of more rapid tumor progression after the first treatment. Controls included untreated mice or animals that received 800 mCi of 90 Y-HSG peptide without prior bsMAb. Body weights and tumor measurements (three dimensions measured by caliper) were made on the day of treatment and then 1-2 times per week until tumor sizes exceeded 2.5 cm 3 . Survival was defined as the time for the tumor to reach 2.5 cm 3 . The largest average starting tumor diameter and volume are given in the figure legends. If body weights decreased by more than 20% without evidence of excessive tumor growth, the mice were euthanized and censored for death due to toxicity. Statistical comparisons of survival were based on the log-rank test of Kaplan-Meier survival curves, as provided by Prism 4.0 software (GraphPad Software Inc., San Diego, CA, USA). Comparisons of % ID/g or tumor/nontumor (T/NT) ratios were determined by a Student's t-test.
Results
Biodistribution
The directly labeled MAb, 111 In-labeled anti-CD20 IgG, IMMU-106, cleared slowly from the blood (Table 1) . Maximum tumor uptake was observed on day 3 (12.074.3% ID/g), but tumor uptake exceeded the concentration in the blood only on day 7 (tumor/blood ratio ¼ 1.470.3). The average T/NT ratios for the major organs did not exceed 2:1 at any time over 7 days.
The 125 I-IMMU-106 Fab 0 Â Fab 0 bsMAb cleared more quickly from the blood principally because of its smaller size, with 3.470.4% ID/g in the blood at 24 h and maximum tumor accretion occurring at 16 h (4.670.5% ID/g). Because it required 48 h before the blood concentration of the 125 I-bsMAb was o1.0% ID/g (0.6970.16 and 1.270.3% ID/g in the blood and tumor, respectively), for pretargeting, the 111 In-HSG peptide injection was delayed until this time. Under these conditions, tumor uptake of the pretargeted 111 In-HSG peptide was 5.671.6% ID/g within 3 h of its injection ( 125 I-bsMAb in tumor at this time was 0.7170.20% ID/g), and T/NT ratios were 1.770.4, 6.670.8, and 1.670.4 for the blood, liver, and In-IMMU-106 IgG group and 0.6-1.0 g for the pretargeted 111 In-HSG peptide group (n ¼ 5 animals at each interval). (Table 1) . By 24 h, tumor accretion decreased to 3.670.5% ID/g ( 125 I-bsMAb decreased to 0.3770.03), but the tumor/blood ratio increased to 10.972.3. Tumor uptake at 3 h of the 111 In-HSG peptide alone (bsMAb not given) was only 0.0770.02% ID/g, which illustrates the specific tumor uptake derived by pretargeting with the bsMAb. AUC data generated from the biodistribution data shown in Table 1 suggest that 800 mCi of the pretargeted 90 Y-HSG peptide would deliver a 33% higher dose to the tumor than 175 mCi of the 90 Y-IgG, and because of its rapid uptake, the average mCi/g in the tumor would be nearly three-fold higher than that achieved with the 90 Y-IgG.
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Therapy studies
The first objective was to assess the safety and efficacy of this pretargeting procedure using a 90 Y dose that had already been shown to be safe and effective in this Ramos model by others using a different pretargeting method. 6 Therefore, a comparison was made of 800 mCi of the Y-HSG peptide also progressed within the first week, but then all tumors regressed significantly, some disappearing completely (Figure 2) . At the termination of the experiment (week 18), five mice had no detectable tumor, and were considered as cured. All animals survived the treatment. Body weights of pretargeted animals, which averaged 18.8570.94 g at the onset of treatment, decreased to 17.9371.93 g 2 weeks later, followed by a steady increase.
In the next studies, the primary objective was to compare pretargeting to directly conjugated (Figure 3a) , and 3/10 animals given the divided 2 Â 500 mCi treatment were tumor-free (Figure 3c ). In contrast, 9/10 animals given a single treatment of 175 mCi of the directly conjugated 90 Y-IMMU-106 IgG progressed, with seven tumors exceeding 2.5 cm 3 within just 7 weeks (Figure 3b ). Among the mice receiving the divided pretargeting treatment regimen, 6/10 had either complete tumor regression or tumors p0.05 cm 3 at the time of the second treatment (4 weeks). Two animals with tumors that were already progressing after the first treatment were removed within 3 weeks of the second pretargeting treatment due to advanced disease. Two tumors that regressed to B0.2 cm 3 regrew within 3 weeks of the second dose, and two animals that had no visible tumor at the time of retreatment had regrowth 2 and 12 weeks later. In the divideddose 90 Y-IMMU-106 IgG treatment group, one animal, whose tumor already regressed 4.6-fold to 0.17 cm 3 when retreated, became tumor-free in the 11th week, while all others progressed to 42.5 cm 3 within 5 weeks of retreatment (Figure 3d ). While it may be understandable that the divided dose for the directly conjugated 90 Y-IMMU-106 IgG did not improve survival, because most of the tumors had already progressed significantly from the onset of treatment, the finding that the divided-dose, pretargeting treatment regimen did not improve survival over the single dose in animals that showed a substantial response to the first treatment, despite increasing the total dose by 20%, was surprising. These data suggest either a failure of the second treatment to effectively target 90 Y to the residual tumor or 90 Y's inability to effectively kill the remaining residual disease because of its long-range beta-emission.
All animals that had received only a single injection of 500 mCi of the bsMAb-pretargeted 90 Y-HSG peptide had no measurable tumor after 23 weeks, thus being cured, in contrast to a 40% survival for therapy with the directly conjugated MAb (Figure 4) . In this particular set of mice, both the pretargeted 90 Y-HSG peptide and the 90 Y-IMMU-106 IgG treatments were more effective than observed in the previous set of animals, reflecting some variability in the treatment response between different studies. Nevertheless, each set of animals showed consistent evidence for a significant treatment advantage for the pretargeting procedure over that of directly conjugated MAb.
Discussion
These studies were initiated primarily to assess the prospects for using a bsMAb-pretargeting procedure 9 to improve the treatment of NHL, in conjunction with a newly developed humanized anti-CD20 MAb. 12 The results clearly demonstrate the superior antitumor effects with this pretargeting procedure using a 90 Y-labeled peptide compared to the directly labeled 90 Y-anti-CD20 IgG. Although the same Ramos tumor model used by Press et al 6 was studied here, it is premature to draw comparisons between these pretargeting procedures. The merits of each type of pretargeting method have been debated, 16, 17 and each clearly improves the treatment response compared to the directly radiolabeled IgG, which should encourage more studies utilizing pretargeting approaches for cancer radioimmunotherapy. Earlier studies have shown the antitumor effects afforded by the unlabeled IMMU-106 IgG, but at higher doses than used in this report. 11 The lack of human CD20 on the normal B cells of nude mice does not allow an assessment of conditions that might be required to optimize targeting when there is a substantial antigen sink, such as in patients where normal B cells also express the antigen. Interestingly, the initial clinical studies using a streptavidin-biotin-pretargeting systems in NHL reported good targeting, but they did not investigate the potential need for predosing patients with an anti-CD20 antibody to improve the targeting of the subsequently administered radiolabeled biotin. 7, 8 These clinical studies are also still too early to gauge the efficacy of this modality; however, both studies suggest that hematologic toxicity will likely be doselimiting in a heavily pretreated NHL patient population. Although additional preclinical assessments of efficacy using other NHL cell lines and toxicity, particularly the possibility for late renal toxicity, should be made in animal models, ultimately clinical studies will be required to gauge the benefits that might be afforded by pretargeted radioimmunotherapy.
Although the bsMAb used here was composed of a humanized Fab 0 conjugated to a murine Fab 0 , fully humanized, single-chain, antigen-binding constructs have been developed for solid tumor RAIT, 10, 15 thus it is feasible to construct the anti-CD20-HSG bsMAb used here, and this should permit repeated dosing because of a reduced risk of immunogenicity. While multiple doses may be an important treatment strategy clinically to reduce bulky disease, the evidence that re-treatment after a highly effective single dose failed to prevent relapse of tumors that were already reduced to barely visible size is suggestive that Y's beta-emission may be too strong to effectively treat small clusters of tumor cells in mice; however, we cannot rule out inadequate targeting of these re-treatment doses, perhaps because of CD20 modulation, saturation, or other factors.
In conclusion, these encouraging results support the development of pretargeting procedures for the RAIT of NHL. With the prospects of being more effective and less myelosuppressive than directly radiolabeled MAbs, pretargeting methods may provide other opportunities for combined modality approaches that could lead to more durable complete responses in NHL and other malignant neoplasms. 
